Section Arrow
TYRA.NASDAQ
- Tyra Biosciences
Quotes are at least 15-min delayed:2026/06/01 14:19 EDT
Regular Hours
Last
 30.68
-2.73 (-8.17%)
Day High 
33.35 
Prev. Close
33.41 
1-M High
37.27 
Volume 
675.09K 
Bid
30.56
Ask
30.76
Day Low
29.65 
Open
33.35 
1-M Low
32.16 
Market Cap 
1.99B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 33.82 
20-SMA 34.2 
50-SMA 35.59 
52-W High 40.65 
52-W Low 8.98 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.18/-2.94
Enterprise Value
1.99B
Balance Sheet
Book Value Per Share
6.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8531+0.4453+109.20%-- 
OTLKOutlook Therapeutics0.8626+0.1326+18.16%-- 
RXRXRecursion Pharmaceuticals3.7478+0.1578+4.40%-- 
GNTAGenenta Science SpA1.7301+0.7001+67.97%-- 
IBRXImmunityBio7.195-0.325-4.32%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.